NeuroSense Therapeutics (NASDAQ: NRSN) provided a comprehensive business update for H1 2025, highlighting progress in its ALS treatment development. The company's lead candidate PrimeC showed promising Phase 2b results, with treatment slowing functional decline by ~40% and improving overall survival by 74% in the per-protocol population.
Key developments include regaining Nasdaq compliance through a $5M private placement, advancing manufacturing capabilities to commercial scale, and preparing for a Phase 3 trial in H2 2025. The company reported reduced R&D expenses of $2.5M (down 32.9% YoY) and maintained stable G&A expenses at $2.2M.
NeuroSense is pursuing regulatory pathways including a planned NOC/c submission in Canada and continues discussions for a potential global pharmaceutical partnership following a Q4 2024 binding term sheet.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.